AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03493854
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin 60 mg/m2 will be administered IV on Day 1 of each cycle of treatment (as part of either ddAC Q2W or AC Q3W) for Cycles 1-4.
Trial: NCT03493854
Drug: Hormone Therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For hormone receptor positive breast cancer, tamoxifen or aromatase inhibitors will be allowed as adjuvant hormone therapy for postmenopausal participants and with ovarian suppression or ablation for premenopausal participants in countries where it has been registered for this indication. Its use must be consistent with the registered label. Hormone therapy is given after chemotherapy and surgery during adjuvant HER2-targeted therapy.
Trial: NCT00328497
Drug: Panzem (2-methoxyestradiol) NCD, Avastin (Bevacizumab)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panzem NCD 1,000 mg, four times daily for 28 consecutive days bevacizumab 5 mg/kg intravenous bolus on Day 1 and Day 15
Trial: NCT02094352
Drug: Control Group + Epidural infusion
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The saline and epidural infusions will be administered over 96 hours with appropriate titration.
Trial: NCT02094352
Drug: Control Group Booster Infusion
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive three saline booster infusions over the course of three months.
Trial: NCT03517566
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily from baseline until week 16
Trial: NCT03517566
Drug: ZPL389 3mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZPL389 3 mg oral powder; once daily from baseline to week 16
Trial: NCT03517566
Drug: ZPL389 10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZPL389 10 mg oral powder; once daily from baseline to week 16
Trial: NCT02239731
Drug: FDX104 (4% Doxycycline)
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FDX104 - 4% or Placebo to be applied twice twice daily during 5 weeks
Trial: NCT03517566
Drug: ZPL389 30mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZPL389 30 mg oral powder; once daily from baseline to week 16
Trial: NCT03517566
Drug: ZPL389 50mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZPL389 50 mg oral powder; once daily from baseline to week 16
Trial: NCT03086330
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semaglutide placebo, gradually increased to 1.0 mg, injected once weekly under the skin (subcutaneously, s.c.) for 30 weeks
Trial: NCT01757535
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identically matching placebo tablets on days 1 to 14 of each 28-day treatment cycle.
Trial: NCT02449031
Drug: TOBI® PODHALER®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02449031
Drug: TOBI®
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: tobramycin inhalation solution, USP
Trial: NCT02449031
Drug: Bethkis®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tobramycin inhalation solution
Trial: NCT02449031
Drug: Cayston®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aztreonam for inhalation solution
Trial: NCT00403481
Drug: Olmesartan medoxomil plus Hydrochlorothiazide
RxNorm normalized name: hydrochlorothiazide / olmesartan medoxomil Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan medoxomil and hydrochlorothiazide combination tablets, once daily, if necessary
Trial: NCT02929589
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ibuprofen 800 milligrams by mouth every 8 hours as needed for pain for 5 days
Trial: NCT02929589
Drug: Opioid Medication
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 to 2 tablets of oxycodone/acetaminophen 5 milligrams/325 milligrams (Qty. 30) by mouth every 4 hours as needed for pain for 5 days
Trial: NCT02929589
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 milligrams of a placebo pill (containing corn starch) to be taken by mouth every 8 hours as needed for pain
Trial: NCT02929589
Drug: Ibuprofen + Opioid medication
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ibuprofen 800 milligrams by mouth every 8 hours as needed for pain for 5 days. 1 to 2 tablets of oxycodone/acetaminophen 5 milligrams/325 milligrams (Qty. 30) by mouth every 4 hours as needed for pain for 5 days
Trial: NCT06041451
Drug: Intravenous Immunoglobulins, Human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients were treated with intravenous immunoglobulin(30g ivgtt qd) for 5 days
Trial: NCT02332057
Drug: Diclofenac plus lidocaine
RxNorm normalized name: diclofenac / lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study nurse will instruct the patients to swallow diclofenac tablets (100 mg) 1 hour before IUD insertion. Three millilitres of the lidocaine gel will be placed on the anterior lip of the cervix . A cotton swab socked in 3 ml of the lidocaine gel will be introduced in the cervical canal till the level of internal os. The cotton swab will be left in place for three minutes. The IUD will be inserted by experienced gynecologists according to the recommendations of manufacture.
Trial: NCT00335218
Drug: Climodien / Lafamme (BAY86-5027)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet daily (2 mg EV + 2 mg DNG)
Trial: NCT02332057
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study nurse will instruct the patients to swallow placebo tablets 1 hour before IUD insertion. Three millilitres of the placebo gel will be placed on the anterior lip of the cervix . A cotton swab socked in 3 ml of the placebo gel will be introduced in the cervical canal till the level of internal os. The cotton swab will be left in place for three minutes. The IUD will be inserted by experienced gynecologists according to the recommendations of manufacture.
Trial: NCT02684097
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo given every two weeks for 24 weeks
Trial: NCT03507634
Drug: Opioid based anesthesia Fentanyl and Remifentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Opioid based anesthesia with Fentanyl and Remifentanyl
Trial: NCT02264626
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: infusion at a rate by 0.025 μg kg-1 min-1 every minute to a maximum of 0.15 μg kg-1 min-1.
Trial: NCT00335218
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet daily
Trial: NCT00396071
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo
Trial: NCT04090229
Drug: ASLAN004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injections of ASLAN004 100 mg/mL will be administered into the thigh or abdomen, except for the 2 inches (5 cm) around the navel.
Trial: NCT04090229
Drug: ASLAN004 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injections of ASLAN004 Placebo will be administered into the thigh or abdomen, except for the 2 inches (5 cm) around the navel.
Trial: NCT03689829
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corresponding placebo s.c. injections.
Trial: NCT02887183
Drug: LCZ696 (sacubitril/valsartan)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCZ696 (sacubitril/valsartan) was supplied as unscored, ovaloid, film-coated oral tablets in the strengths of 24/26 mg, 49/51 mg, 97/103 mg to be taken twice daily (bid)
Trial: NCT04181476
Drug: Sunscreening Agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four different sunscreens
Trial: NCT03313557
Drug: Wee-1 kinase inhibitor AZD1775
RxNorm normalized name: PROTEIN KINASE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive AZD1775 300 mg orally once daily. Days 1 to 5 and 8 to 12 of a 21 day cycle (ie, 5 days on and 2 days off for Weeks 1 and 2 of a 21-day cycle). All patients must receive a serotonin receptor 3 (5-HT3) antagonist, ondansetron (Zofran) 8 mg orally/IV or granisetron (Kytril) 1 mg orally/IV prior to each dose of AZD1775. Dexamethasone 4 mg orally/IV will be given with each AZD1775 dose at a minimum on the first day of dosing of AZD1775 of every 5 day dosing period, unless contraindicated or not well-tolerated.
Trial: NCT03955705
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% Sodium chloride (normal saline or NSS)
Trial: NCT00810667
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: twice daily oral dose
Trial: NCT04168112
Drug: Prednisolone Acetate
RxNorm normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: post-crosslinking eye drop prednisolone acetate given in a tapering schedule over 1 month
Trial: NCT03768908
Drug: Artemether-lumefantrine
RxNorm normalized name: artemether-lumefantrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three day treatment with Artemether-lumefantrine, 2 doses a day under direct observation
Trial: NCT02505750
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00636246
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, orally once per day for 8 weeks
Trial: NCT03091543
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 capsules of placebo
Trial: NCT03091543
Drug: BIA 6-512 25 mg dose
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule of 25 mg plus 1 capsule of placebo
Trial: NCT03091543
Drug: BIA 6-512 50 mg dose
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 capsules of 25 mg
Trial: NCT03091543
Drug: BIA 6-512 100 mg dose
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule of 100 mg plus 1 capsule of placebo
Trial: NCT03091543
Drug: BIA 6-512 200 mg dose
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 capsules of 100 mg
Trial: NCT00839683
Drug: simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, 20 mg, Single Dose
Trial: NCT00839683
Drug: simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral, 40 mg, Single Dose
Trial: NCT01997788
Drug: The intravenous patient-controlled analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intravenous injection of morphine using the patient-controlled analgesia machine
Trial: NCT01997788
Drug: Demerol on demand
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Demerol 25 mg intravenously when pain scores more than 5.
Trial: NCT02127840
Drug: Synacthen infusion during adrenal venous sampling
RxNorm normalized name: adrenal cortex extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenal venous sampling during Synacthen infusion
Trial: NCT00687271
Drug: MK-6213
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-6213 160 mg for 4 weeks.
Trial: NCT00687271
Drug: Placebo for MK-6312 160 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02652468
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV for 2 days
Trial: NCT02323373
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml of saline solution administered with anesthesia during 10 minutes
Trial: NCT01966120
Drug: Placebo to BF-200 ALA gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The reference product was a placebo (a nanoemulsion gel formulation similar to the Investigational Medicinal Product (IMP), but without the active ingredient). The placebo was packaged, assigned to each patient, and administered in the same way as the IMP.
Trial: NCT04116840
Drug: MT1002 for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study drug will be administered by an intravenous bolus dose followed by an infusion of 4 hours.
Trial: NCT00461630
Drug: simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg simvastatin tablet orally per day as background LDL-lowering treatment allocated at entry based on previous statin treatment and total cholesterol level
Trial: NCT04608396
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo taken daily for up to 52 weeks, until relapse.
Trial: NCT01058642
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00442897
Drug: simvastatin (+) ezetimibe
RxNorm normalized name: ezetimibe / simvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: simvastatin (+) ezetimibe 10/20mg, tablet, once daily, 12wks(sub group:24wks)
Trial: NCT04498182
Drug: AR-15512 Ophthalmic Solution Vehicle
RxNorm normalized name: OPTI VET AR 0.025 % / 0.3 % Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ophthalmic solution vehicle administered via topical ocular instillation
Trial: NCT01704495
Drug: AZD5069
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD5069 oral capsules self-administered twice daily.
Trial: NCT01704495
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral capsules self-administered twice daily.
Trial: NCT03174535
Drug: Qilong capsules (QLC), produced by Jining Huaneng Pharmaceutical Factory Co., Ltd.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The recommended dosage of QLC was 0.4g each time, 3 times a day. The course of treatment was 12 weeks.
Trial: NCT02367118
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00390871
Drug: Fentanyl/Dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00390871
Drug: Fentanyl/Propofol
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00390871
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00256412
Drug: Eicosapentaenoic acid (EPA) 0.7 grams/day or 1.5 grams/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo and Omega 3 capsules. All participants receive 4 capsules with either 0, 2, or 4 capsules containing omega 3.
Trial: NCT00256412
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 capsules of placebo each day
Trial: NCT03188289
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is the control group treated with a placebo gel.
Trial: NCT02588612
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be used as a lymphodepleting chemotherapy.
Trial: NCT01676441
Drug: cellgram-spine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesenchymal stem cells transplantation
Trial: NCT01268943
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral pills, 1000mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation.
Trial: NCT01268943
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral pills, 1200mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation.
Trial: NCT01268943
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral pills, 1400mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation.
Trial: NCT00506415
Drug: Placebo to 15 cm^2 patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of rivastigmine transdermal patch 15 cm\^2.
Trial: NCT00506415
Drug: Placebo to 10 cm^2 patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of rivastigmine transdermal patch 10 cm\^2.
Trial: NCT01954056
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: • 7 day course of hydrocortisone (hydrocortisone sodium succinate, plain; will not have benzyl alcohol) given through intravenous line or by intramuscular injection if no intravenous line).~1 mg/kg loading dose x 1; 0.5 mg/kg q 6 hours x 12 doses; 0.5 mg/kg q 12 hours x 4 doses; 0.5 mg/kg q day x 1 dose
Trial: NCT01954056
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 days of intravenous or intramuscular placebo (normal saline in equal volume)~1 mg/kg loading dose x 1; 0.5 mg/kg q 6 hours x 12 doses; 0.5 mg/kg q 12 hours x 4 doses; 0.5 mg/kg q day x 1 dose
Trial: NCT03328507
Drug: BLI4900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BLI4900 Bowel Preparation
Trial: NCT03328507
Drug: PEG Control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyethylene glycol-based bowel preparation
Trial: NCT01742130
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03451890
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral capsule
Trial: NCT00392340
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01703260
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roflumilast placebo-matching dose
Trial: NCT00053196
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5 mg/sq m/day IV infusion Days 1, 3, \& 6 for HLA-identical donor transplants and Days 1, 3, 6, \& 11 for MUD \& 9/10 related donor transplants
Trial: NCT01268943
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral pills, 1500mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation.
Trial: NCT03422068
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet formulation
Trial: NCT02927951
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150mg bid
Trial: NCT04122586
Drug: Tongxieyaofang(granule)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take this granule twice a day,one bag for each time,one hour after a meal,for 4 weeks
Trial: NCT00351195
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00116818
Drug: GW685698X aqueous nasal spray
RxNorm normalized name: Pen-Aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03742518
Drug: Topical SM04554 solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study medication application will be performed by the individual subject at approximately the same time each day.
Trial: NCT02215200
Drug: Placebo (for ATG)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline administered by IV infusion to mimic ATG
Trial: NCT02215200
Drug: Placebo (for GCSF)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo prepared to mimic 6mg subcutaneous injection of GCSF
Trial: NCT01438892
Drug: tDMARDs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional DMARDs for RA
Trial: NCT01438892
Drug: biodmards
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biologic DMARDs
Trial: NCT03032510
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03437213
Drug: Total intravenous anesthesia group
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction of general anesthesia with fentanyl, (1mcg / kg), propofol (1-2 mg / kg), atracurium (0.5 mg / kg), intubation. Anesthesia maintained using Propofol (4-6) mg/kg/h, fentanyl (0.5-1) μg/kg/h. to be modified according to analgesic needs and hemodynamics. 10mg atracurium when the 2nd twitch of train of four appears.
Trial: NCT03404518
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen as first line therapy every 6 hours as needed for pain control
Trial: NCT01291849
Drug: Dixon up-and-down method
RxNorm normalized name: Kool-Down
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The target Ce of remifentanil was determined by the response of the previous patient using Dixon's up-and-down method. If the patients did not cough throughout peri-extubation period, the extubation was defined as a smooth emergence, and the predetermined concentration of remifentanil for the subsequent patient was decreased by 0.5 ng ml-1. Similarly, if the patient cough anytime around extubation it was considered as failed smooth emergence and the predetermined concentration was increased by 0.5 ng ml-1 for the next patient. The patients were enrolled until getting at least six cross-over pairs in Dixon sequential allocation method.
Trial: NCT01052181
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 sachets monthly for an year